- Poster presentation
- Open Access
Role of platelet activation in the cardiovascular complications associated with HIV infection: differential effect of abacavir versus tenofovir
© Francisci et al; licensee BioMed Central Ltd. 2010
Published: 8 November 2010
Abacavir use has been associated with an increased risk of ischemic cardiovascular events in several cohort studies, but the pathogenic mechanisms are still unknown. Recently Martinez et al. observed no differences in markers of inflammation, endothelial dysfunction, insulin resistance or hypercoagulability in HIV infected persons treated with either abacavir or tenofovir. While several studies have shown endothelial dysfunction in HIV-infected patients, only a few data are available on the involvement of platelets. Aim of our study was to evaluate markers of platelet activation and endothelial dysfunction in HIV infection comparing patients treated with abacavir or tenofovir.
In a retrospective, case-control study, the time course of some endothelial (MCP-1, sVCAM-1) and platelet activation markers (sPLA2, sGPV, sP-sel) was examined in 62 HIV-infected patients, before starting HAART and after 6-12 months of therapy with either Abacavir (n=31) or Tenofovir (n=31). Data were compared with those from 20 untreated HIV-infected patients at diagnosis and after 6 months and 10 healthy matched controls.
Soluble P-selectin (sP-sel), sPLA2, soluble vascular cell adhesion molecule-1 (sVCAM-1) and monocyte chemoattractant protein-1 (MCP-1) were significantly higher in HIV-infected patients than in healthy controls. During 6-12 months of follow-up, we found no significant differences between abacavir and tenofovir-treatment for endothelial markers, while sPLA2 (2113.6±39.5 vs 2742.5±29.7pg/ml, p<0.05) and sPsel (524±53.2 vs 713.47±20.3ng/ml, p<0.05) increased significantly in the abacavir group as compared with the tenofovir-treated group. sGPV, the platelet glycoprotein V major fragment released upon thrombin cleavage, was increased after 6-12 months as compared to baseline in both treatment groups (Abacavir: 89.7±13.7 vs 118.64±15.3 ng/ml Tenofovir: 133.5±10.7 vs 157.36±11.2, p<0.05). In naïve patients, not treated with HAART, significantly increased plasma markers of endothelial dysfunction sPsel and sPLA2 were confirmed at diagnosis, as compared with healthy controls, with no changes upon follow-up.
Our results confirm that chronic HIV infection induces endothelial dysfunction but indicate that a short-term treatment with abacavir enhances also some parameters of platelet activation, suggesting a role of platelets too in the increased incidence of ischemic cardiovascular events in HIV-infected patients treated with abacavir.
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.